Dwight Evans is not exactly dominating the news cycle right now. Zero Google News stories in the last 24 hours. The loudest thing social media could dig up about him this week was a Bluesky post noting he and Jim Rice were teammates for 15 years — the baseball Dwight Evans, to be clear. So in the absence of a news peg handed to us on a silver platter, we'll work with what the disclosure filings actually show: a House Ways and Means member who sold five stocks over the last 90 days, missed the market's direction on every single one of them, and still found time to vote yes on a cluster of banking bills that have nothing to do with his committee jurisdiction.
The Record, Unvarnished
Per Blind Trust's disclosure tracker, Evans has filed five trades since late March. Every one of them was a sale. His full scored sample across eight trades clocks in at zero wins out of eight, with a mean 30-day alpha of negative 5.7 percent against the S&P 500.
Members are required to disclose. They are not required to be good at this.
The five recent sales: American Tower (AMT) on May 11, then Intel (INTC), Quanta Services (PWR), and Thermo Fisher Scientific (TMO) all on May 7, and Micron Technology (MU) back on March 24. All fall in the $1,000–$15,000 range except Micron, which cleared $15,000–$50,000. Small positions by congressional portfolio standards, but the directional calls are what they are.
The Math on Each Trade
Start with the least-bad outcome. The American Tower sale on May 11 generated essentially flat alpha: negative 0.0 percent over the following 30 days versus the index. Evans sold it, the stock went nowhere meaningful relative to the market.
The Intel sale that same week did a little worse: negative 1.5 percent alpha. The Quanta Services sale came in at negative 7.7 percent alpha — he sold it and watched it beat the market by 7.7 points.
The worst of the recent batch: Thermo Fisher Scientific, also sold May 7, at negative 7.8 percent alpha over 30 days. Thermo Fisher makes scientific instruments and life-science equipment. Evans sits on the Ways and Means Health subcommittee. That's the one trade in the recent batch that carries a committee-overlap flag in the data. The subcommittee covers healthcare financing and policy. Thermo Fisher operates squarely in the healthcare supply chain. The trade was a sale in the $1,000–$15,000 range and the stock subsequently beat the market by nearly 8 points.
Evans sold. Thermo Fisher went up. Ways and Means Health is his turf. The receipts are public.
Then There's Micron
The single largest disclosed trade in the window is the Micron Technology sale on March 24, at $15,000–$50,000. The 30-day alpha: negative 14.1 percent. Micron, which makes memory chips and is as tariff-sensitive and macro-cyclical a semiconductor name as exists, proceeded to outrun the S&P 500 by 14 points in the month after Evans sold it.
No committee overlap on Micron. Evans doesn't sit on Science, Space, and Technology. He doesn't sit on Energy and Commerce. It's just a trade — a $15,000–$50,000 sale of a chip stock that, by the data, could not have been timed worse.
Eight trades scored. Zero positive. The best is flat alpha. The worst is down 14.1. The mean is negative 5.7. If you wanted to construct a model for what not to do, this sample would be instructive.
What He Was Voting On While Selling
The same week Evans was selling Intel, Quanta, and Thermo Fisher, he was casting votes on a set of banking-related bills. On May 20, he voted yes on the American Access to Banking Act, yes on the Community Bank Deposit Access Act of 2025, and yes on the Keeping Deposits Local Act. All three passed.
Banking regulation sits under the House Financial Services Committee. Evans is on Ways and Means. These are floor votes, not committee-level decisions, and they don't carry a conflict-of-interest angle on Evans specifically. He's one of 435 members casting floor votes on bills drafted in committees he doesn't sit on.
The timing is what it is: selling a cluster of equities across tech, infrastructure, and healthcare, then voting yes on three bills designed to expand consumer access to banking services, all in the same five-day window. No flagged overlap in the data.
The Veterans Votes
On May 21, Evans voted no on both the Veterans 2nd Amendment Protection Act and the Sharri Briley and Eric Edmundson Veterans Benefits Expansion Act of 2026. Both passed without him. He had voted yes the day prior on the Fiscal Year 2025 Veterans Affairs Major Medical Facility Authorization Act, so his veterans-bill record for the week is two nays and one yea.
None of these touch his committees. Ways and Means handles tax, trade, and healthcare financing. Veterans affairs is the remit of the House Committee on Veterans' Affairs. These are floor votes, full stop.
The social feed has seven total posts about Evans right now, with vote-tracking bots doing most of the lifting. The congressman is not a trending topic. He is a man who voted on some bills and filed some trades, and the trades have been, by the disclosed record, uniformly bad calls.
The Bigger Picture
Evans's full alpha record across eight scored trades is 0-for-8 with a mean of negative 5.7 percent. The best trade in the set is the AMT sale at flat alpha. The second best is the INTC sale at negative 1.5 percent. Every other trade is negative, with three of them in the negative 7 to negative 14 range.
The one angle that carries structural weight is the Thermo Fisher sale on May 7. Committee overlap with Ways and Means Health, negative 7.8 percent alpha — the stock beat the market by nearly 8 points after Evans got out. A disclosure system exists to surface exactly this combination: committee jurisdiction and a realized directional miss. The data doesn't assert anything about timing or motive. It surfaces the overlap and leaves the question open.
The full disclosure record is at Blind Trust. The votes are at Congress.gov. The math on 0-for-8 doesn't require interpretation.
Readers get to bring their own opinion.